TriSalus Life Sciences Inc
TLSI7.080USD
-0.380-5.09%
Market hours （ET）Quotes delayed by 15 min
353.23MMarket Cap
LossP/E TTM
More Details of TriSalus Life Sciences Inc Company
TriSalus Life Sciences, Inc. is an oncology-focused medical technology company. The Company is seeking to transform outcomes for patients with solid tumors by integrating its delivery technology with standard-of-care therapies, and with its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 agonist, for a range of different therapeutic and technology applications. The Company’s platform includes devices that utilize a proprietary drug delivery technology and a clinical-stage investigational immunotherapy. The Company’s two Food and Drug Administration (FDA)-cleared devices use its proprietary Pressure-Enabled Drug Delivery (PEDD) approach to deliver a range of therapeutics: the TriNav Infusion System for hepatic arterial infusion of liver tumors and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. PEDD technology is a novel delivery approach designed to address the anatomic limitations of arterial infusion for the pancreas.
TriSalus Life Sciences Inc Info
Ticker SymbolTLSI
Company nameTriSalus Life Sciences Inc
IPO dateDec 18, 2020
CEOSzela (Mary T)
Number of employees110
Security typeOrdinary Share
Fiscal year-endDec 18
Address6272 W. 91st Ave.
CityWESTMINSTER
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code80031
Phone14153368917
Websitehttps://trisaluslifesci.com/
Ticker SymbolTLSI
IPO dateDec 18, 2020
CEOSzela (Mary T)
Company Executives of TriSalus Life Sciences Inc
Name
Name/Position
Position
Shareholding
Change
Mr. David Patience
Mr. David Patience
Chief Financial Officer
Chief Financial Officer
265.00K
+32.50%
Dr. Bryan F. Cox, Ph.D.
Dr. Bryan F. Cox, Ph.D.
Chief of Research
Chief of Research
155.29K
+34.70%
Ms. Jodi Devlin
Ms. Jodi Devlin
Chief of Clinical Operations
Chief of Clinical Operations
73.53K
+212.53%
Mr. Gary Gordon
Mr. Gary Gordon
Independent Director
Independent Director
6.25K
--
Mr. William Valle
Mr. William Valle
Independent Director
Independent Director
--
--
Mr. Kerry Hicks
Mr. Kerry Hicks
Independent Director
Independent Director
--
--
Dr. Richard B. Marshak
Dr. Richard B. Marshak
Chief Commercial Officer
Chief Commercial Officer
--
--
Dr. Arjun (J.J.) Desai, M.D.
Dr. Arjun (J.J.) Desai, M.D.
Independent Director
Independent Director
--
--
Ms. Mary T. Szela
Ms. Mary T. Szela
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Mats L. Wahlstrom
Mr. Mats L. Wahlstrom
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. David Patience
Mr. David Patience
Chief Financial Officer
Chief Financial Officer
265.00K
+32.50%
Dr. Bryan F. Cox, Ph.D.
Dr. Bryan F. Cox, Ph.D.
Chief of Research
Chief of Research
155.29K
+34.70%
Ms. Jodi Devlin
Ms. Jodi Devlin
Chief of Clinical Operations
Chief of Clinical Operations
73.53K
+212.53%
Mr. Gary Gordon
Mr. Gary Gordon
Independent Director
Independent Director
6.25K
--
Mr. William Valle
Mr. William Valle
Independent Director
Independent Director
--
--
Mr. Kerry Hicks
Mr. Kerry Hicks
Independent Director
Independent Director
--
--
Revenue Breakdown
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
11.21M
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Thu, Nov 27
Updated: Thu, Nov 27
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Frankenius Equity AB
13.99%
Utmost Group PLC
6.78%
Pallotta (James Joseph)
4.29%
Nantahala Capital Management, LLC
4.08%
Wahlstrom (Mats)
3.24%
Other
67.62%
Shareholders
Shareholders
Proportion
Frankenius Equity AB
13.99%
Utmost Group PLC
6.78%
Pallotta (James Joseph)
4.29%
Nantahala Capital Management, LLC
4.08%
Wahlstrom (Mats)
3.24%
Other
67.62%
Shareholder Types
Shareholders
Proportion
Corporation
25.76%
Individual Investor
18.14%
Hedge Fund
7.44%
Investment Advisor
6.14%
Investment Advisor/Hedge Fund
4.95%
Research Firm
0.67%
Family Office
0.14%
Pension Fund
0.09%
Bank and Trust
0.04%
Other
36.64%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
101
8.97M
17.99%
+2.93M
2025Q2
91
22.46M
64.15%
+2.60M
2025Q1
92
21.99M
65.21%
+1.88M
2024Q4
78
20.16M
66.55%
+1.10M
2024Q3
134
17.38M
61.59%
-17.28M
2024Q2
138
18.39M
67.10%
-19.84M
2024Q1
139
17.82M
67.47%
-22.09M
2023Q4
148
24.02M
151.82%
-25.48M
2023Q3
144
23.91M
151.67%
-9.24M
2023Q2
127
7.82M
99.41%
-22.42M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Frankenius Equity AB
6.99M
14.02%
+759.00K
+12.18%
Jul 31, 2025
Utmost Group PLC
1.98M
3.97%
-20.31K
-1.02%
Jun 20, 2025
Pallotta (James Joseph)
2.15M
4.3%
+350.13K
+19.50%
Jun 13, 2025
Nantahala Capital Management, LLC
2.00M
4.01%
+2.00M
--
Jun 30, 2025
Wahlstrom (Mats)
1.62M
3.24%
+322.68K
+24.91%
Jul 31, 2025
HW Investment Partners LLC
1.37M
2.75%
--
--
Jul 31, 2025
AWM Investment Company, Inc.
1.25M
2.51%
+1.25M
--
Jun 30, 2025
The Vanguard Group, Inc.
814.39K
1.63%
+327.77K
+67.36%
Jun 30, 2025
Sands Point LLC
1.13M
2.26%
+1.13M
--
Jun 13, 2025
Gilder Gagnon Howe & Co. LLC
1.09M
2.19%
+265.62K
+32.10%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0.02%
iShares Russell 2000 Value ETF
0.01%
Global X Russell 2000 ETF
0%
Proshares Ultra Russell 2000
0%
ProShares UltraPro Russell2000
0%
ProShares Hedge Replication ETF
0%
iShares Russell 2000 ETF
0%
iShares Russell 2000 Growth ETF
0%
iShares Micro-Cap ETF
Proportion0.02%
iShares Russell 2000 Value ETF
Proportion0.01%
Global X Russell 2000 ETF
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
iShares Russell 2000 ETF
Proportion0%
iShares Russell 2000 Growth ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of TriSalus Life Sciences Inc?
The top five shareholders of TriSalus Life Sciences Inc are:
Frankenius Equity AB holds 6.99M shares, accounting for 14.02% of the total shares.
Utmost Group PLC holds 1.98M shares, accounting for 3.97% of the total shares.
Pallotta (James Joseph) holds 2.15M shares, accounting for 4.30% of the total shares.
Nantahala Capital Management, LLC holds 2.00M shares, accounting for 4.01% of the total shares.
Wahlstrom (Mats) holds 1.62M shares, accounting for 3.24% of the total shares.
Frankenius Equity AB holds 6.99M shares, accounting for 14.02% of the total shares.
Utmost Group PLC holds 1.98M shares, accounting for 3.97% of the total shares.
Pallotta (James Joseph) holds 2.15M shares, accounting for 4.30% of the total shares.
Nantahala Capital Management, LLC holds 2.00M shares, accounting for 4.01% of the total shares.
Wahlstrom (Mats) holds 1.62M shares, accounting for 3.24% of the total shares.
What are the top three shareholder types of TriSalus Life Sciences Inc?
The top three shareholder types of TriSalus Life Sciences Inc are:
Frankenius Equity AB
Utmost Group PLC
Pallotta (James Joseph)
Frankenius Equity AB
Utmost Group PLC
Pallotta (James Joseph)
How many institutions hold shares of TriSalus Life Sciences Inc (TLSI)?
As of 2025Q3, 101 institutions hold shares of TriSalus Life Sciences Inc, with a combined market value of approximately 8.97M, accounting for 17.99% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -46.16%.
What is the biggest source of revenue for TriSalus Life Sciences Inc?
In FY2025Q2, the -- business generated the highest revenue for TriSalus Life Sciences Inc, amounting to -- and accounting for --% of total revenue.
